QL1706 combined with Chemotherapy

DRUG2 trials

Sponsors

Anhui Provincial Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital

Conditions

Breast CancerImmune Checkpoint InhibitorsNSCLC (Advanced Non-small Cell Lung Cancer)Neoadjuvant TherapyQL1706

Phase 2

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

RecruitingNCT07330596

Anhui Provincial Cancer HospitalNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2025-10-30End: 2028-02-28Target: 96Updated: 2026-01-09

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Not yet recruitingNCT07372079

Tianjin Medical University Cancer Institute and HospitalBreast Cancer, Immune Checkpoint Inhibitors, Neoadjuvant Therapy +1

Start: 2026-04-05End: 2029-12-30Target: 40Updated: 2026-01-28